Abiraterone, a CYP17 inhibitor, blocks androgen biosynthesis in multiple tissue types. In combination with prednisone, it is approved as a first-line treatment for metastatic castration-resistant prostate cancer. We present a case of rhabdomyolysis associated with abiraterone therapy resulting in acute on chronic kidney injury in a patient with metastatic castration-resistant prostate cancer. Strict monitoring should be employed in patients started on abiraterone who have additional risk factors for developing rhabdomyolysis.
Huerta-AlardinALVaronJMarikPE. Bench-to-bedside review: rhabdomyolysis – an overview for clinicians. Crit Care2005; 9: 158–169.
3.
KhanFY. Rhabdomyolysis: a review of the literature. Netherland J Med2009; 67: 272–283.
4.
OshimaY. Characteristics of drug-associated rhabdomyolysis: analysis of 8,610 cases reported to the U.S. Food and Drug Administration. Intern Med2011; 50: 845–853.
5.
BoschXPochEGrauJM. Rhabdomyolysis and acute kidney injury. New Engl J Med2009; 361: 62–72.
6.
MelliGChaudhryVCornblathDR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine2005; 84: 377–385.
7.
CoitDGThompsonJAAlgaziAet al.NCCN Guidelines Insights: Melanoma, Version 3.2016. J Natl Comprehens Cancer Network: JNCCN2016; 14: 945–958.
MooreDCMooreA. Abiraterone-induced rhabdomyolysis: a case report. J Oncol Pharm Pract: official publication of the International Society of Oncology Pharmacy Practitioners2015; 23: 148–151.
10.
NeyraJARochaNABhargavaRet al.Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case report. BMC Nephrol2015; 16: 118–118.
